With tumor progression, tumor cells can acquire resistance to TGF-β growth inhibition by downregulation or mutation of the TGF-β receptors (TGF-βR) [23] or TGF-β pathway downstream effectors such as Smad4 [24], a coactivator in the canonical TGF-β pathway [25]. Here, SMAD4 is linked to neoplasm.